K R Maravilla1, M P Smith2, J Vymazal3, M Goyal4, M Herman5, J J Baima6, R Babbel7, M Vaneckova8, J Žižka9, C Colosimo10, M Urbańczyk-Zawadzka11, M Mechl12, A K Bag13, S Bastianello14, E Bueltmann15, T Hirai16, T Frattini17, M A Kirchin18, G Pirovano19. 1. From the MR Research Laboratory (K.R.M.), University of Washington, Seattle, Washington kmarav@uw.edu. 2. Department of Radiology (M.P.S.), Beth Israel Deaconess Medical Center, Boston, Massachusetts. 3. Department of Radiology (J.V.), Na Homolce Hospital, Prague, Czech Republic. 4. Seaman Family MR Research Centre (M.G.), University of Calgary, Calgary, Alberta, Canada. 5. Department of Radiology (M.H.), University Hospital Olomouc, Olomouc, Czech Republic. 6. Clinical Radiologists Service Corporation (J.J.B.), Memorial Medical Center, Springfield, Illinois. 7. Good Samaritan Regional Medical Center (R.B.), Corvallis, Oregon. 8. Department of Magnetic Resonance (M.V.), General University Hospital, Prague, Czech Republic. 9. Department of Diagnostic Radiology (J.Ž.), University Hospital Hradec Králové and Faculty of Medicine in Hradec Králové, Charles University, Prague, Czech Republic. 10. Istituto di Radiologia (C.C.), Policlinico "Agostino Gemelli," Rome, Italy. 11. Department of Radiology (M.U.-Z.), John Paul II Hospital, Krakow, Poland. 12. Department of Radiology (M.M.), University Hospital Brno-Bohunice, Brno, Czech Republic. 13. Department of Radiology (A.K.B.), University of Alabama at Birmingham Medical Center, Birmingham, Alabama. 14. Department of Neuroradiology (S.B), University of Pavia, Pavia, Italy. 15. Institute for Diagnostic and Interventional Neuroradiology (E.B.), Hannover, Germany. 16. Department of Diagnostic Radiology (T.H.), Kumamoto University, Honjo, Kumamoto, Japan. 17. Ospedale Valduce (T.F.), Como, Italy. 18. Global Medical and Regulatory Affairs (M.A.K.), Bracco Imaging SpA, Milan, Italy. 19. Global Medical and Regulatory Affairs (G.P.), Bracco Diagnostics, Monroe, New Jersey.
Abstract
BACKGROUND AND PURPOSE: Gadobutrol (Gadavist) and gadoteridol (ProHance) have similar macrocyclic molecular structures, but gadobutrol is formulated at a 2-fold higher (1 mol/L versus 0.5 mol/L) concentration. We sought to determine whether this difference impacts morphologic contrast-enhanced MR imaging. MATERIALS AND METHODS: Two hundred twenty-nine adult patients with suspected or known brain tumors underwent two 1.5T MR imaging examinations with gadoteridol or gadobutrol administered in randomized order at a dose of 0.1 mmol/kg of body weight. Imaging sequences and T1 postinjection timing were identical for both examinations. Three blinded readers evaluated images qualitatively and quantitatively for lesion detection and for accuracy in characterization of histologically confirmed brain tumors. Data were analyzed by using the Wilcoxon signed rank test, the McNemar test, and a mixed model. RESULTS:Two hundred nine patients successfully completed both examinations. No reader noted a significant qualitative or quantitative difference in lesion enhancement, extent, delineation, or internal morphology (P values = .69-1.00). One hundred thirty-nine patients had at least 1 histologically confirmed brain lesion. Two readers found no difference in the detection of patients with lesions (133/139 versus 135/139, P = .317; 137/139 versus 136/139, P = .564), while 1 reader found minimal differences in favor of gadoteridol (136/139 versus 132/139, P = .046). Similar findings were noted for the number of lesions detected and characterization of tumors (malignant/benign). Three-reader agreement for characterization was similar for gadobutrol (66.4% [κ = 0.43]) versus gadoteridol (70.3% [κ = 0.45]). There were no significant differences in the incidence of adverse events (P = .199). CONCLUSIONS: Gadoteridol and gadobutrol at 0.1 mmol/kg of body weight provide similar information for visualization and diagnosis of brain lesions. The 2-fold higher gadolinium concentration of gadobutrol provides no benefit for routine morphologic imaging.
RCT Entities:
BACKGROUND AND PURPOSE:Gadobutrol (Gadavist) and gadoteridol (ProHance) have similar macrocyclic molecular structures, but gadobutrol is formulated at a 2-fold higher (1 mol/L versus 0.5 mol/L) concentration. We sought to determine whether this difference impacts morphologic contrast-enhanced MR imaging. MATERIALS AND METHODS: Two hundred twenty-nine adult patients with suspected or known brain tumors underwent two 1.5T MR imaging examinations with gadoteridol or gadobutrol administered in randomized order at a dose of 0.1 mmol/kg of body weight. Imaging sequences and T1 postinjection timing were identical for both examinations. Three blinded readers evaluated images qualitatively and quantitatively for lesion detection and for accuracy in characterization of histologically confirmed brain tumors. Data were analyzed by using the Wilcoxon signed rank test, the McNemar test, and a mixed model. RESULTS: Two hundred nine patients successfully completed both examinations. No reader noted a significant qualitative or quantitative difference in lesion enhancement, extent, delineation, or internal morphology (P values = .69-1.00). One hundred thirty-nine patients had at least 1 histologically confirmed brain lesion. Two readers found no difference in the detection of patients with lesions (133/139 versus 135/139, P = .317; 137/139 versus 136/139, P = .564), while 1 reader found minimal differences in favor of gadoteridol (136/139 versus 132/139, P = .046). Similar findings were noted for the number of lesions detected and characterization of tumors (malignant/benign). Three-reader agreement for characterization was similar for gadobutrol (66.4% [κ = 0.43]) versus gadoteridol (70.3% [κ = 0.45]). There were no significant differences in the incidence of adverse events (P = .199). CONCLUSIONS:Gadoteridol and gadobutrol at 0.1 mmol/kg of body weight provide similar information for visualization and diagnosis of brain lesions. The 2-fold higher gadolinium concentration of gadobutrol provides no benefit for routine morphologic imaging.
Authors: Martin Rohrer; Hans Bauer; Jan Mintorovitch; Martin Requardt; Hanns-Joachim Weinmann Journal: Invest Radiol Date: 2005-11 Impact factor: 6.016
Authors: Z Seidl; J Vymazal; M Mechl; M Goyal; M Herman; C Colosimo; M Pasowicz; R Yeung; B Paraniak-Gieszczyk; B Yemen; N Anzalone; A Citterio; G Schneider; S Bastianello; J Ruscalleda Journal: AJNR Am J Neuroradiol Date: 2012-03-01 Impact factor: 3.825
Authors: M Koenig; G Schulte-Altedorneburg; M Piontek; A Hentsch; P Spangenberg; C Schwenke; A Harders; L Heuser Journal: Eur Radiol Date: 2013-07-04 Impact factor: 5.315
Authors: K R Maravilla; D San-Juan; S J Kim; G Elizondo-Riojas; J R Fink; W Escobar; A Bag; D R Roberts; J Hao; C Pitrou; A J Tsiouris; E Herskovits; J B Fiebach Journal: AJNR Am J Neuroradiol Date: 2017-06-29 Impact factor: 3.825
Authors: M Vaneckova; M Herman; M P Smith; M Mechl; K R Maravilla; J Weichet; M V Spampinato; J Žižka; F J Wippold; J J Baima; R Babbel; E Bültmann; R Y Huang; J-H Buhk; A Bonafé; C Colosimo; S Lui; M A Kirchin; N Shen; G Pirovano; A Spinazzi Journal: AJNR Am J Neuroradiol Date: 2015-07-16 Impact factor: 3.825
Authors: Ray R Zhang; Cynthia Choi; Christina L Brunnquell; Reinier Hernandez; Anatoly N Pinchuk; Joseph G Grudzinski; Paul A Clark; Alan B McMillan; Anjon Audhya; Justin Jeffrey; John S Kuo; Jamey P Weichert Journal: Invest Radiol Date: 2022-06-22 Impact factor: 10.065
Authors: Rajat Chauhan; Nagwa El-Baz; Robert S Keynton; Kurtis T James; Danial A Malik; Mingming Zhu; Ayman El-Baz; Chin K Ng; Paula J Bates; Mohammad Tariq Malik; Martin G O'Toole Journal: Nanomaterials (Basel) Date: 2019-05-07 Impact factor: 5.076
Authors: Adam J Shuhendler; Deju Ye; Kimberly D Brewer; Magdalena Bazalova-Carter; Kyung-Hyun Lee; Paul Kempen; K Dane Wittrup; Edward E Graves; Brian Rutt; Jianghong Rao Journal: Sci Rep Date: 2015-10-06 Impact factor: 4.379
Authors: Chetan C Shah; Maria Vittoria Spampinato; Hemant A Parmar; Osama A Raslan; Paolo Tomà; Doris D M Lin; Josef Vymazal; Cesare Colosimo; David S Enterline Journal: Pediatr Radiol Date: 2021-05-05